Hologic Inc (HOLX)
78.69
+0.65
(+0.83%)
USD |
NASDAQ |
Nov 21, 16:00
78.69
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 18.28B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 8.54% |
Valuation | |
PE Ratio | 23.63 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.638 |
Price to Book Value | 3.563 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.4941 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 46.24% |
Profile
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
URL | http://www.hologic.com |
Investor Relations URL | https://investors.hologic.com |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Mid Cap/Blend |
Next Earnings Release | Jan. 31, 2025 (est.) |
Last Earnings Release | Nov. 04, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
URL | http://www.hologic.com |
Investor Relations URL | https://investors.hologic.com |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Mid Cap/Blend |
Next Earnings Release | Jan. 31, 2025 (est.) |
Last Earnings Release | Nov. 04, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |